Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

19:03 EST 5th March 2015 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 14,000+

Extremely Relevant

Neuromyelitis Optica May Be Linked With Epstein-Barr Virus

Persistent, active replication of Epstein-Barr virus might play a role in neuromyelitis optica (NMO) and also might contribute to the immunological alterations that play a role in the disorder, Japanese researchers say. Reuters Health Information

Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab

FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease

SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborative partner, Memorial Sloan Kettering Cancer Center (MSK) has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for Atara's optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) in the treatme...

Clinical utility gene card for: X-linked immunodeficiency with magnesium defect, Epstein–Barr virus infection, and neoplasia (XMEN)

Epstein-Barr Viral Infections - Pipeline Review, H2 2014

Recently added to the BioPortfolio report store, Epstein-Barr Viral Infections - Pipeline Review, H2 2014 is a new report from GlobalData published on 2014-11-17. This 54-page report is available in PDF from $2000. Epstein-Barr Viral Infections - Pipeline Review, H2 2014 Summary Global Markets Direct’s, ‘Epstein-Barr Viral Infections - Pipeline Review, H2 2014’, provides an overview of the...

Epstein-Barr Viral Infections - Pipeline Review, H1 2015

Recently added to the BioPortfolio report store, Epstein-Barr Viral Infections - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-01-29. This 56-page report is available in PDF from $2000. Epstein-Barr Viral Infections - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Epstein-Barr Viral Infections - Pipeline Review, H1 2015’, provides an over...

Cell Medica raises L50M series B

Cell therapy developer Cell Medica Ltd. (London, U.K.) raised L50 million ($78.2 million) in a series B round led by Imperial Innovations. Invesco Perpetual and Woodford Investment Management also participated.Cell Medica's CMD-003 (Cytorex EBV) is i...

Atara gains on breakthrough designation

Atara Biotherapeutics Inc. (NASDAQ:ATRA) gained $0.92 to $20.48 after its partner, Memorial Sloan Kettering Cancer Center, received breakthrough therapy designation for EBV-CTL to treat rituximab-refractory lymphoproliferative disease associated with...

Valganciclovir May Curb CMV, EBV in Living Kidney Donors

Antiviral prophylaxis with valganciclovir in living kidney donors may reduce transmission of cytomegalovirus (CMV) and Epstein-Barr virus (EBV), a pilot study suggests. Reuters Health Information

Q&A: Françoise Barré-Sinoussi

Françoise Barré-Sinoussi and Luc Montagnier were jointly awarded the 2008 Nobel prize in Physiology or Medicine for their discovery of HIV in 1983. Three decades on, Barré-Sinoussi is director of the Retroviral Infections unit at the Pasteur Insti...

Relevant

Study Shows that DNA of Latent EBV May Cause Cancer; Center for the Biology of Chronic Disease Comments on the Latest Study

DNA of the Epstein Barr Virus is linked to epithelial (surface cell) malignancies and malignant transformation (cancer), according to a study published in the Journal of Pathology on December 11, 2014. (1) CBCD reviews the study and recommends two natural EBV remedies. Rochester, NY (PRWEB) January 18, 2015 “Infected with the Epstein Barr Virus (EBV)? The Center for the Biology of Chronic Disea...

[Articles] Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses

Many studies on environmental factors associated with multiple sclerosis have caveats casting doubts on their validity. Data from more and better-designed studies are needed to establish robust evidence. A biomarker of Epstein-Barr virus (anti-EBNA I...

Knowing HIV Status Crucial in Cancer Treatment

People living with HIV infection have a high incidence of AIDS-related cancers—Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer—and they’re at increased risk for other cancers as well. Yet only 41% of cancer survivors have been tested ...

Canadian Ebola vaccine licensed to Merck

Global pharma giant Merck & Co Inc. has bought the worldwide commercial rights to NewLink Genetics Corp’s experimental Ebola virus vaccine rVSV-EBOV. The vaccine platform is based on an attenuated strain of vesicular stomatitis virus that has been modified to express an Ebola virus protein that plays an essential role in establishing virus infection. The [&hellip The post Canadian E...

[Correspondence] Is Canada patent deal obstructing Ebola vaccine development?

A decade ago, Canadian Government scientists invented a vaccine against Ebola virus (VSV-ZEBOV). That vaccine is based on a live attenuated vesicular stomatitis virus, and has several known advantages over the other vaccine candidates in clinical tri...

The Problem with Cancer Vaccines

You can’t treat a heterogeneous disease with a homogeneous treatment. That was the takeawy message from Vaccinogen’s founder at the World Vaccines Congress Europe Vaccine Nation caught up with Michael Hanna, the founder of Vaccinogen and creator of autologous patient-specific tuumor cell vaccine OncoVAX, to discuss why ther have been so many highprofile cancer vaccine failures and [&...

Zoetis gets conditional OK on pig virus vaccine

Animal health company Zoetis has received conditional approval from federal regulators for a vaccine that helps fight a virus that has killed millions of piglets since it started showing up in the United States last year.The Florham Park, New Jersey, company said Wednesday that its vaccine for the porcine epidemic diarrhea virus should be available to veterinarians and pig farmers this month. The...

Next-gen polio vaccine tackles wild virus emergency

Vaccine technology being developed at The University of Queensland could hold the key to completely eradicating polio by removing live virus from the vaccine production process.

Lighting up a new path for novel synthetic polio vaccine

(Diamond Light Source) Scientists from the UK and USA are using technology that helped in the design of a new synthetic vaccine to combat the foot and mouth disease virus to target the virus that causes polio. The vaccine for FMDV does not contain th...

Interview: The Problem with Cancer Vaccines

You can’t treat a heterogeneous disease with a homogeneous treatment. That was the takeawy message from Vaccinogen’s founder at the World Vaccines Congress Europe Vaccine Nation caught up with Michael Hanna, the founder of Vaccinogen and creator of autologous patient-specific tuumor cell vaccine OncoVAX, to discuss why ther have been so many highprofile cancer vaccine failures and [&...

[Articles] Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial

The live recombinant measles-virus-based chikungunya vaccine had good immunogenicity, even in the presence of anti-vector immunity, was safe, and had a generally acceptable tolerability profile. This vaccine is the first promising measles-virus-based...

Measles vaccine in modified form also effective against Chikungunya virus

A modified, conventional measles vaccine has the potential to act against the Chikungunya virus. This is the result of a study at the University Clinic for Clinical Pharmacology of the MedUni Wien (Medical University of Vienna), which has now been pu...

Influenza Vaccine May Protect Against Guillain-Barré Syndrome

Influenza is known to increase the risk for GBS. A new study has predicted that the seasonal influenza vaccine may reduce the risk. Medscape Medical News

ViroCyt and I&L Biosystems Launch Virus Counter® 3100 at the World Vaccine Congress in Brussels

October 2, 2014 ViroCyt, LLC, the leader in rapid virus quantification, announced today that, in partnership with I&L Biosystems GmbH, it is formally launching the Virus Counter® 3100 in Europe at the World Vaccine Congress to be held October 13-15 in Brussels, Belgium. “The Virus Counter 3100 is the marquee analytical tool for quickly quantifying […] The post ViroCyt and I&L...

Australian virus might be answer to effective Ebola vaccine

An experimental Ebola vaccine made using an Australian virus called Kunjin might help in the fight against the deadly Ebola virus, an international study led by The University of Queensland has found.


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks